A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase Beta

Administered By

Awarded By

Contributors

Start/End

  • June 18, 2018 - January 31, 2021